Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Investigating Speech Sequencing in Neurotypical Speakers and Persons With Disordered Speech
NCT05437159 · View on ClinicalTrials.gov ↗
Study Summary
Persistent developmental stuttering affects more than three million people in the United States, and it can have profound adverse effects on quality of life. Despite its prevalence and negative impact, stuttering has resisted explanation and effective treatment, due in large part to a poor understanding of the neural processing impairments underlying the disorder. The overall goal of this study is to improve understanding of the brain mechanisms involved in speech motor planning and how these are disrupted in neurogenic speech disorders, like stuttering. The investigators will do this through an integrated combination of experiments that involve speech production, functional MRI, and non-invasive brain stimulation. The study is designed to test hypotheses regarding the brain processes involved in learning and initiating new speech sound sequences and how those processes compare in persons with persistent developmental stuttering and those with typical speech development. These processes will be studied in both adults and children. Additionally, these processes will be investigated in patients with neurodegenerative speech disorders (primary progressive aphasia) to further inform the investigators understanding of the neural mechanisms that support speech motor sequence learning. Together these experiments will result in an improved account of the brain mechanisms underlying speech production in fluent speakers and individuals who stutter, thereby paving the way for the development of new therapies and technologies for addressing this disorder.
Conditions Studied
Interventions
- DEVICE Sham tDCS
- BEHAVIORAL Learning of non-native phoneme combinations: 6 training sessions
- BEHAVIORAL Learning of non-native phoneme combinations: 1 training session
- BEHAVIORAL Learning of novel multisyllabic nonwords
- DEVICE Anodal tDCS
Study Locations (3)
Massachusetts
- Massachusetts General Hospital — Boston
- Boston University — Boston
Michigan
- University of Michigan — Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-04-03 |
| Est. Completion | 2026-05 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05437159
The ClinicalTrials.gov registry entry for NCT05437159 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston University Charles River Campus, which has 148 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Stuttering, Developmental appearing as the primary indexed condition, and to 5 interventions — of which Sham tDCS is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05437159 reports 3 study locations spanning 2 distinct geographic areas — top geographies include Massachusetts, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05437159 about?
NCT05437159 is a clinical study titled "Investigating Speech Sequencing in Neurotypical Speakers and Persons With Disordered Speech". Persistent developmental stuttering affects more than three million people in the United States, and it can have profound adverse effects on quality of life. Despite its prevalence and negative impact, stuttering has resisted explanation and effective treatment, due in large part to a poor understan...
What is the current status of trial NCT05437159?
This trial is currently recruiting. It is a NA study. The enrollment target is 2 participants. The study started on 2023-04-03. Estimated completion is 2026-05.
What conditions does trial NCT05437159 study?
This clinical trial studies the following conditions: Stuttering, Developmental, Aphasia, Primary Progressive. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05437159?
The interventions under investigation include: Sham tDCS (DEVICE), Learning of non-native phoneme combinations: 6 training sessions (BEHAVIORAL), Learning of non-native phoneme combinations: 1 training session (BEHAVIORAL), Learning of novel multisyllabic nonwords (BEHAVIORAL), Anodal tDCS (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05437159?
This trial is sponsored by Boston University Charles River Campus, which has 148 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05437159 being conducted?
This trial has 3 study locations across Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.